FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to a molecule which binds to V (VEGF-C) vascular endothelium growth factor and vascular endothelium growth factor D (VEGF-D) and can be used in medicine for angiogenesis regulation.
EFFECT: molecule consisting of the first three Ig-like domains of VEGFR-3 with deletion of the N-glycosylation site in VEGFR-3 domain 1 and attached by its C-terminal amino acid to the N-terminal amino acid of the immunoglobulin constant domain fragment has improved pharmacokinetic properties.
6 cl, 5 dwg, 6 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED PROTEINS CONTAINING PDGF AND VEGF BINDING PARTS, AND METHODS FOR USE THEREOF | 2014 |
|
RU2692652C2 |
| HYBRID PROTEINS BASED ON HUMAN Notch3 AS TRAPS-INHIBITORS OF Notch3 SIGNAL TRANSMISSION | 2009 |
|
RU2567662C2 |
| MODIFIED BINDING PROTEINS, INHIBITING INTERACTION OF VEGF-A RECEPTOR | 2011 |
|
RU2605309C2 |
| PEPTIDES OF DIRECTED ACTION OF VEGFR-1/NRP-1 | 2008 |
|
RU2488592C2 |
| NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN PDGFRA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2821574C1 |
| COMPOSITIONS OF HUMANISED NOTCH FUSED PROTEINS AND METHODS OF TREATING | 2008 |
|
RU2532830C2 |
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| IMPROVED METHODS OF TREATING VASCULARISED MALIGNANT TUMORS | 2015 |
|
RU2692248C2 |
| BINDING PROTEINS INHIBITING VEGF-A RECEPTOR INTERACTION | 2009 |
|
RU2550258C2 |
| OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES | 2016 |
|
RU2763916C2 |
